When metastatic cancer cells need to avoid a threat, they simply reprogram themselves. Rice University scientists are beginning to get a handle on how they survive hostile environments.
Members of Rice’s Center for Theoretical Biological Physics (CTBP) and cancer metabolism researchers at Baylor College of Medicine have created a basic framework of how cancer cells — whether in tumors or as single cells — adapt when their attempts to metastasize are blocked by drugs or the body’s immune system. Understanding the cells’ strategies could someday help scientists design therapies that keep them in check.
Their model shows a direct connection between gene regulation and metabolic pathways and how cancer cells take advantage of it to adapt to hostile environments, a process known as metabolic plasticity.
In particular, the team led by physicists Herbert Levine and José Onuchic and postdoctoral fellow Dongya Jia looked at oxidative phosphorylation (OXPHOS) and glycolysis, metabolic processes that provide cells with the energy and chemical building blocks they need to proliferate.
From their model, they detailed for the first time a direct association between the activities of two protein players, AMP-activated protein kinase (AMPK) and hypoxia-inducible factor-1 (HIF-1), the master regulators of OXPHOS and glycolysis, respectively, with the activities of three major metabolic pathways: glucose oxidation, glycolysis and fatty acid oxidation.
Their theoretical model was experimentally supported by Baylor cancer mitochondrial metabolism researchers led by Dr. Benny Abraham Kaipparettu.
The new study appears in the Proceedings of the National Academy of Sciences.
“A lot of early cancer papers focus on the Warburg effect, when cancer cells primarily use glycolysis even in the presence of oxygen,” Onuchic said. “This is true, but it’s not like cancer cells give up on other mechanisms. The more aggressive they become, the more they are able to use any available choice to acquire energy. Our model shows how that’s possible.”
“Only recently have people paid attention to OXPHOS,” Jia added. “But they don’t really understand how cancer cells regulate these two metabolic phenotypes. We want to know how cancer cells orchestrate them. Since there is an extensive cross-talk between gene regulation and metabolic pathways, we think it’s necessary to simultaneously look at these two different aspects of cancer metabolism.”
The researchers said their model helped the team hone in on critical processes that traditional genome-scale metabolic models might miss. “We start with simple models where we can figure out completely what’s going on, and then we add details to that scaffold without losing the basic understanding of how the system’s working,” Levine said.
Jia’s mathematical model details connections that allow cancer cells to adopt three stable metabolic states. One is a glycolytic state, characterized by high activity of HIF-1 and high activity of the glycolytic pathway. The second is an OXPHOS state, characterized by high activity of AMPK and high activity of such OXPHOS pathways as glucose oxidation and fatty acid oxidation.
The third is a hybrid metabolic state characterized by high activity of AMPK and HIF-1 and of the glycolysis and OXPHOS pathways. The Rice model revealed the presence of both HIF-1 and AMPK can lead to the hybrid state that is difficult for current cancer therapies to address.
The researchers also found the hybrid metabolic state can be promoted by the stabilization of HIF-1 and the elevated production rate of mitochondrial reactive oxygen species (ROS) in cancer cells relative to normal cells. ROS are chemically active molecules that are important to signaling but at high levels can damage cells.
Kaipparettu’s Baylor team backed up the theory using gene expression data from breast cancer patients and metastatic triple negative breast cancer experimental models. Experimental evidence showed that repressing glycolytic activity in the cells activated AMPK and enhanced OXPHOS. The reverse was also true. But a combination of inhibitors that attacked both glycolysis and OXPHOS successfully eliminated the cells’ metabolic plasticity.
“We’re trying to push the field of metabolic modeling towards more flexibility, allowing for the decision-making processes we see in cells,” Levine said. “And here we’re coupling genes to metabolism in a way that’s rather novel.
“It’s still a limited view of all the metabolic pathways,” he said. “There are yet other possibilities that are not included in our model. We eventually need to tell a more complete story to really know what’s happening.”
Co-authors of the paper are former Rice postdoctoral researcher Mingyang Lu, an assistant professor at The Jackson Laboratory, Bar Harbor, Maine; postdoctoral associates Kwang Hwa Jung and Jun Hyoung Park of Baylor; and Rice alumnus Linglin Yu. Levine is an adjunct professor of bioengineering at Rice and a University Distinguished Professor at Northeastern University. Onuchic is the Harry C. and Olga K. Wiess Chair of Physics, a professor of physics and astronomy, of chemistry and of biochemistry and cell biology and co-director of the CTBP.
The research was supported by the National Science Foundation; National Cancer Institute; The Jackson Laboratory; the National Institute of General Medical Sciences; the Department of Defense; the Collaborative Faculty Research Investment Program, the Dan L. Duncan Comprehensive Cancer Center and the Charles A. Sammons Cancer Center, all at Baylor; and the Breast Cancer Research Foundation.
#VAResearchNewsBrief: The American College of Physicians @acpinternists released 4 guidance statements on #breastcancer screening for average-risk women. A researcher from the @VAMinneapolis was part of the guideline committee. @VeteransHealth #VAResearch https://t.co/vR1SDnsteD https://t.co/HHj4DPD7cI
@glenda_webb_ @TeamCJCorrea @astros @OrbitAstros Thanks, Glenda, for sharing this great photo!
The underwater dive memorial, called “Circle of Heroes,” will eventually feature 24 concrete statues representing the men and women in the U.S. Air Force, Army, Coast Guard, Marines and Navy https://t.co/VOvuck7S6s via @MiamiHerald
As researchers work to create therapies to target #AML, safety is one of the critical challenges, according to our Dr. Elias Jabbour: https://t.co/S0Wggy1zlD @TargetedOnc #leusm #endcancer
An afternoon swim is a great way to help your kids stay active during the summer months. Make sure they are safe in the water with these tips from Dr. Katherine Leaming-Van Zandt. https://t.co/pVyiG4Jlk3 #swimming #pediatrics
RT @UTHpromotion: Join @UTexasSPH @ProfKimBaker, DrPH, at the #BlackMaternalHealth Summit in Houston on Aug 29 for #BlackMaternalMentalHeal…
RT @NBTStweets: “We feel an obligation because this has happened in our family…So this is our way to pay it forward…We feel an obligation t…
Take a warm bath 1-2 hours before bedtime to get better sleep, @UTHealth researchers find: https://t.co/Bi53wLDvwU
How our #prehab program is helping patients improve strength, endurance and functional capacity ahead of #cancer treatment: https://t.co/eKBYtRtWN5 @DrNgoHuang #endcancer https://t.co/1YQ2YeRYqA
Our Dr. Farhad Ravandi says combining CAR-Ts and BiTEs could “potentially be very interesting and very effective.” #immunotherapy #endcancer https://t.co/Jo7t9JwP9h
Meet the Army Doctor Who Will Spend Seven Months at the International Space Station https://t.co/0FpePtBHWV via @MilitaryOfficer
CHI St. Luke's Health@CHI_StLukes
Last year, Baylor St. Luke’s became the first in Texas to use the #PulseRider, an innovative device used to treat wide-neck bifurcation aneurysms. And now, our team is one of the first to use WEB, a new device in the treatment of complex #BrainAneurysms: https://t.co/QxomC5ne3w https://t.co/kzOvdKt9zO
Deadly fungal disease may be linked to climate change, study suggests: https://t.co/TKlCyiWWxW
University of Houston@UHouston
RT @Brad_Carpenter: How did I not know this little jewel existed on our @UHouston campus?? Get out and explore your campus today. #CoogLead…
@elephande Thank you for sharing your comment with us. Houston Methodist strives to deliver the highest quality, service and care to all our patients. We would like to discuss this issue with you. Please call 713.441.4100 or visit https://t.co/wPtazimDiv